Journal article
Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors
SJ Clarke, CS Karapetis, P Gibbs, N Pavlakis, J Desai, M Michael, NC Tebbutt, TJ Price, J Tabernero
Critical Reviews in Oncology Hematology | Published : 2013
Abstract
During the last 20 years there have been major therapeutic developments in colorectal cancer (CRC) with the introduction of multiple novel therapeutic agents into routine clinical practice. This has improved survival in both the adjuvant and advanced disease settings. However, improvements have come with substantial increases in expense to the community and potential toxicity to the patient. There has been substantial research to identify tumour factors in CRC that predict treatment response and survival outcomes. This research has identified clinically useful predictive biomarkers to aid clinical decision making, such as the presence or absence of KRAS gene mutations which can determine the..
View full abstractGrants
Funding Acknowledgements
The following authors declare no conflict of interests: Stephen Clarke, Chris Karapetis and Niall Tebbutt. Josep Tabernero: supported by study grants (Amgen, Genentech, Merck-Serono and Roche Products); advisory board member (Amgen, Genentech, Merck-Serono and Roche Products); travel support (Roche Products); and payment for lectures (Amgen, Merck-Serono and Roche Products). Nick Pavlakis: advisory board, speaking honoraria and travel support (Roche Products and Merck Serono). Michael Michael: advisory board member (Roche Products). Jayesh Desai: honoraria and research funding (Roche Products). Peter Gibbs: advisory board member (Sanofi Aventis and Roche Products). Timothy Price: advisory board member (Merch-Serono, Amgen and Roche).